News | April 07, 2024
Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India
Subscribe To Our Newsletter & Stay Updated
